Intercept Pharmaceuticals Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 341

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $592M

Intercept Pharmaceuticals General Information

Description

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 305 Madison Avenue
  • Morristown, NJ 07960
  • United States
+1 (646)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 305 Madison Avenue
  • Morristown, NJ 07960
  • United States
+1 (646)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intercept Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 08-Nov-2023 $592M Completed Generating Revenue
10. Secondary Transaction - Open Market Completed Generating Revenue
9. 2PO 19-Feb-2019 Completed Generating Revenue
8. Secondary Transaction - Open Market 09-Oct-2015 Completed Generating Revenue
7. 2PO 18-Jun-2013 Completed Generating Revenue
6. IPO 11-Oct-2012 Completed Generating Revenue
5. Later Stage VC (Series C) 09-Aug-2012 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 25-Jan-2010 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 29-Jul-2008 $25M $29.2M Completed Clinical Trials - Phase 2
2. Early Stage VC 04-May-2005 $1.25M $4.25M Completed Product Development
To view Intercept Pharmaceuticals’s complete valuation and funding history, request access »

Intercept Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 13,888,889 $0.001000 $0.11 $1.8 $1.8 1x $1.8 9.92%
To view Intercept Pharmaceuticals’s complete cap table history, request access »

Intercept Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat
Drug Discovery
Morristown, NJ
341 As of 2022

Watertown, MA
 

Morrisville, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intercept Pharmaceuticals Competitors (59)

One of Intercept Pharmaceuticals’s 59 competitors is Enanta Pharmaceuticals, a Formerly VC-backed company based in Watertown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enanta Pharmaceuticals Formerly VC-backed Watertown, MA
TG Therapeutics Corporation Morrisville, NC
Pliant Therapeutics Formerly VC-backed San Francisco, CA
Supernus Formerly VC-backed Rockville, MD
Damora Therapeutics ( Drug Discovery) Formerly VC-backed Waltham, MA
You’re viewing 5 of 59 competitors. Get the full list »

Intercept Pharmaceuticals Patents

Intercept Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025250918-A1 Novel compositions Pending 30-May-2024
WO-2025240669-A1 Crystalline forms of a farnesoid x receptor agonist Pending 15-May-2024
WO-2024163640-A2 Methods and intermediates for the preparation of bile acid derivatives Inactive 01-Feb-2023
WO-2024163640-A3 Methods and intermediates for the preparation of bile acid derivatives Inactive 01-Feb-2023
WO-2024102925-A1 Crystalline forms of a farnesoid x receptor agonist Inactive 11-Nov-2022 C07J9/005
To view Intercept Pharmaceuticals’s complete patent history, request access »

Intercept Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intercept Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated September, 30, 2025

26.5 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Biotechnology

Subindustry

of 394

Rank

Percentile

To view Intercept Pharmaceuticals’s complete esg history, request access »

Intercept Pharmaceuticals FAQs

  • When was Intercept Pharmaceuticals founded?

    Intercept Pharmaceuticals was founded in 2002.

  • Where is Intercept Pharmaceuticals headquartered?

    Intercept Pharmaceuticals is headquartered in Morristown, NJ.

  • What is the size of Intercept Pharmaceuticals?

    Intercept Pharmaceuticals has 341 total employees.

  • What industry is Intercept Pharmaceuticals in?

    Intercept Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Intercept Pharmaceuticals a private or public company?

    Intercept Pharmaceuticals is a Private company.

  • What is the current valuation of Intercept Pharmaceuticals?

    The current valuation of Intercept Pharmaceuticals is .

  • What is Intercept Pharmaceuticals’s current revenue?

    The current revenue for Intercept Pharmaceuticals is .

  • How much funding has Intercept Pharmaceuticals raised over time?

    Intercept Pharmaceuticals has raised $219M.

  • Who are Intercept Pharmaceuticals’s competitors?

    Enanta Pharmaceuticals, TG Therapeutics, Pliant Therapeutics, Supernus, and Damora Therapeutics ( Drug Discovery) are some of the 59 competitors of Intercept Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process